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disorder appears to exceed 415,000 [31,905 x (2.75/35%)] + [17,000 x (3.4/35%)]. 
On average, 1.5 work days are lost by staff following patient assault at an annual cost 
of $444.4 million (based on hourly pay rates for nurses and doctors of $41 and $162, 
respectively). CONCLUSIONS: Rapid and effective de-escalation of agitation among 
patients with schizophrenia or bipolar disorder seeking care in the ED may reduce the 
incidence and associated costs of staff assaults.
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OBJECTIVES: The aim of this research was to evaluate patient characteristics, length 
of stay (LOS), and costs among children and adolescents hospitalized in the United 
States (US) for ADHD. METHODS: The study used data from 2000–2006 in the 
Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS). 
Patients included were children (6–11 years old) and adolescents (12–17 years old) 
that were hospitalized with a primary diagnosis of ADHD (ICD-9-CM 314.00 or 
314.01). Data collected includes age, gender, race, payer type, admission source, 
admission type, geographic region, hospital status, year admitted, mean LOS and 
mean costs. RESULTS: Among children, 28,247 patients met inclusion criteria and 
83.74% were male. Medicaid was the most common form of health insurance 
(68.97%) followed by private insurance (26.67%). The majority of patients were 
hospitalized in urban locations (96.69%) and were admitted from the emergency room 
(33.75%). Mean (SE) LOS was 10.76 days (0.85) and mean (SE) costs were $10,106 
($1,358). Among adolescents, 21,612 patients met inclusion criteria and 75.70% were 
male. Medicaid was the most common form of health insurance (57.38%) followed 
by private insurance (36.99%). The majority of patients were hospitalized in urban 
locations (93.83%) and admitted from the emergency room (38.77%). Mean (SE) 
LOS was 8.66 days (0.66) and mean (SE) costs were $7886 ($1387). The number of 
hospitalizations for ADHD in each individual year from 2000–2006 was fairly con-
stant for both children and adolescents. CONCLUSIONS: Children and adolescents 
hospitalized for ADHD carry a substantial economic burden to the US health care 
system. The majority of these patients are male, come from urban locations and have 
Medicaid as their primary form of health insurance. Health care decision makers 
should be aware of the burden of ADHD in these populations. Research evaluating 
the impact of behavioural and/or pharmalogical ADHD treatment on hospitalizations 
should be explored.
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OBJECTIVES: Estimate the current societal costs of opioid abuse, dependence, and 
misuse. METHODS: Costs associated with opioid abuse were grouped into three 
major categories: health care, workplace, and criminal justice. Two general principles 
were adopted to estimate costs: 1) a quantity method, which multiplies the number 
of opioid abuse patients by the estimated cost per opioid abuse patient, and, 2) an 
apportionment method, which begins with the overall costs of drug abuse for a cost 
component and apportions the share associated with opioid abuse based on the rela-
tive prevalence of opioid abuse to overall drug abuse. Excess health care costs per 
patient were based on analysis of two claims datasets: a privately-insured population 
and Florida Medicaid. Other data/information was derived from publicly-available 
secondary resources (e.g., academic research, government reports and surveys). 
RESULTS: Total societal costs of opioid abuse in the U.S. were estimated at $54.5 
billion annually (2008 dollars). Disaggregated by major category, workplace costs 
accounted for $25.1 billion (46%), health care costs accounted for $24.2 billion 
(44%), and criminal justice costs accounted for $5.2 billion (10%). Workplace costs 
were driven by lost earnings due to premature death ($11.1 billion) and reduced 
compensation/lost employment associated with opioid abuse ($7.8 billion). Health 
care costs consisted primarily of excess medical and prescription drug costs for opioid 
abuse patients ($23.0 billion). Criminal justice costs were largely made up of cor-
rectional facility costs attributable to opioid abuse ($2.3 billion) and police protection 
costs attributable to opioid abuse ($1.5 billion). CONCLUSIONS: The costs of opioid 
abuse represent a substantial and growing economic burden for society in the U.S. 
The increasing prevalence of abuse and related spending suggest an even greater 
societal burden in the future. Recent initiatives developed by the government, clini-
cians, and the health care industry may help reduce the burden of opioid abuse.
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OBJECTIVES: Compare health care costs of patients with post-traumatic stress dis-
order (PTSD) to those of patients with major depressive disorder (MDD) in U.S. 
Medicaid and privately-insured populations. METHODS: Patients with ≥2 PTSD 
diagnoses (ICD-9-CM: 309.81) on/after January 1, 1999 and ≥1 PTSD diagnosis on/
after January 1, 2003 were identiﬁed from Medicaid claims data from Florida, 
Missouri, and New Jersey (1999–2007) and from a privately-insured claims database 
(1999–2008). The index date was deﬁned as the ﬁrst PTSD diagnosis on/after 1/1/2003 
that was not the ﬁrst overall PTSD diagnosis. PTSD patients had continuous eligibility 
for the 6-month baseline period before and 12-month study period following their 
index date and were ages 18–64 during the study period. Potential MDD controls 
(ICD-9-CM: 296.2, 296.3) without PTSD diagnosis were identiﬁed using similar 
selection criteria. MDD controls were matched to PTSD patients on age, gender, 
state/region, employment status, index year, and race (for Medicaid patients). 
Study period direct costs, calculated as reimbursements in 2008 dollars to third-party 
payers for medical services and prescription drugs, were compared between PTSD 
patients and matched MDD controls using nonparametric bootstrapping. RESULTS: 
In the baseline period, PTSD patients had higher rates of other mental disorders 
(e.g. anxiety, bipolar disorder), and higher average direct costs than MDD controls 
both in the Medicaid and privately-insured populations. Among Medicaid patients, 
PTSD patients also had lower average Charlson Comorbidity Index compared 
with MDD controls. Average study period direct costs were higher for PTSD patients 
than MDD controls ($18,753 vs. $17,990 for Medicaid and $10,960 vs. $10,024 for 
privately-insured, both p < 0.05). The difference in direct costs was driven by higher 
mental health-related costs for PTSD patients than for MDD controls. CONCLU-
SIONS: PTSD patients had approximately 4–10% higher direct costs in the 12-month 
study period compared to MDD controls driven by higher mental-health related direct 
costs.
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OBJECTIVES: To examine patterns of health care utilization and costs in patients 
with generalized anxiety disorder (GAD) beginning treatment with benzodiazepine 
anxiolytics as add-on therapy to selective serotonin reuptake inhibitors (SSRI) or 
venlafaxine. METHODS: Using a large US health insurance claims database, we 
identiﬁed all persons with evidence of GAD (ICD-9-CM diagnosis code 300.02) who 
were receiving treatment (≥90 days) with SSRIs or venlafaxine between January 1, 
2003 and December 31, 2007. Among these patients, we then selected those who 
began add-on therapy with a benzodiazepine anxiolytic. Designating the date of initial 
receipt of a benzodiazepine the “index date”, we compiled all health care claims over 
the 6-month period preceding this date (“pre-index”) and the 12-month period fol-
lowing it (“follow-up”). Patients with incomplete data were excluded. Health care 
utilization and costs were then examined during these periods. RESULTS: A total of 
2131 patients met all study inclusion criteria. Mean age was 43 years; 73% were 
women. Patients averaged 32 days of therapy with benzodiazepines, however, dura-
tion of therapy was >90 days, for 14% of patients. In general, levels of health care 
utilization during the ﬁrst 6 months of follow-up were higher than during pre-index; 
during the second 6 months of follow-up, however, they were somewhat lower than 
pre-index. Median (IQR) total health care costs were $2672 ($1465-$4960) during 
pre-index, $2897 ($1525–5663) during the ﬁrst 6 months of follow-up, and $2581 
($1270-$5107) during the second 6 months of follow-up. CONCLUSIONS: Overall 
health care utilization and associated costs increased following initial GAD diagnosis. 
Although the duration of treatment is typically brief, some patients receive benzodi-
azepine anxiolytics as add-on therapy to SSRIs or venlafaxine for periods longer than 
90 days, which is not recommended due to risks of dependency and sedation.
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OBJECTIVES: To investigate the health care resource utilization and cost-of-illness 
in patients with schizophrenia in Sweden. METHODS: Data on socio-demographics 
and disease-related health care resource use for 2412 patients were collected using 
registry data for the period 2006–2008. Data on health care visits and inpatient days 
were obtained from the Northern Stockholm psychiatric clinic, while data on phar-
maceuticals, sick leave and early retirement were obtained from the national pharma-
ceutical registry and the Swedish social insurance agency, respectively. Costs for 
community care were not available on individual level in the databases, and were 
therefore obtained from previous studies. The study was conducted from a societal 
perspective, with indirect costs valued according to the human capital method. 
RESULTS: The average annual cost per patient with schizophrenia in the period 
2006–2008 was estimated at 348,300o (US$68,800) in 2009 prices. Total costs 
increased by 8% from 2006 to 2008, mainly because of increased indirect costs. 
Outpatient care represented 5%, inpatient care 9%, pharmaceuticals 3%, community 
care 24% and productivity losses 59% of total costs. Costs (excluding community 
care cost, which was not available on the individual level) were signiﬁcantly and posi-
tively correlated with lower functioning as assessed with GAF (General Assessment of 
Functioning). Costs in the lowest GAF class (GAF < 50) were almost three times as 
large as in the highest GAF class (GAF > = 70). Men had signiﬁcantly higher indirect 
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costs than women, but differences in other cost items were not signiﬁcant. The mean 
age was 51 years (SD 14 years) and 54% (SD 0.50) were men. CONCLUSIONS: As 
the societal costs for patients with schizophrenia are high and strongly related to global 
functioning, attempts to improve functioning by means of effective treatment and 
rehabilitation might not only decrease suffering for patient’s and relatives, but also 
reduce societal cost of illness.
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OBJECTIVES: While the economic costs of substance abuse have been extensively 
examined in the published literature, information on the costs of abuse of prescription 
opioids is more limited, despite this rapidly growing problem in the US. The National 
Survey of Drug Use and Health (NSDUH) estimated that, between 2001 and 2006, 
the number of persons using prescription pain relievers for nonmedical purposes 
increased from 3.5 million to 5.2 million. We sought to estimate the economic burden 
of prescription opioid abuse in the US. METHODS: We estimated the current eco-
nomic burden of prescription opioid abuse in the US in terms of direct substance abuse 
treatment, medical complications, productivity loss, and criminal justice. Utilizing 
information from NSDUH, we distributed our broad cost estimates among the various 
drugs of abuse, including prescription opioids, down to the individual drug level. Data 
sources included the National Expenditures for Mental Health Services and Substance 
Abuse Treatment; the CDC’s mortality database and HIV/AIDS Surveillance Report; 
the Ofﬁce of National Drug Control Policy’s estimates of the economic costs of drug 
abuse in the US; the US DOJ’s Uniform Crime Statistics, proﬁles of prison and jail 
inmates and expenditure and employment reports; and the published literature. 
RESULTS: The estimated 2006 total cost of prescription opioid abuse was $53.4 
billion, of which $42 billion (79%) was attributable to productivity loss, $8.2 billion 
(15%) to criminal justice costs, $2.2 billion (4%) to abuse treatment, and $944 million 
to medical complications (2%). In our analysis of costs by speciﬁc prescription opioids, 
ﬁve drugs—OxyContin, oxycodone, hydrocodone, propoxyphene, and methadone—
accounted for two thirds of all prescription-opioid-attributable costs. CONCLU-
SIONS: The great majority of the economic costs of opioid abuse, 94%, are accounted 
for by lost productivity and crime. The burden of prescription opioid abuse in the US 
is high and will likely continue to grow.
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OBJECTIVES: Antipsychotics in long-acting formulations (“depot”) are often tar-
geted for patients with schizophrenia who are at high risk of relapse and hospitaliza-
tion. Little information is available on the change in the rate or cost of psychiatric 
hospitalization following the initiation of depot antipsychotics. This retrospective 
mirror-image study used a U.S. health insurance claims database to assess changes in 
the rate, duration, and cost of psychiatric hospitalizations following initiation of long-
acting (depot) antipsychotics in patients with schizophrenia. METHODS: Patients 
younger than 65 who were diagnosed with schizophrenia on at least 2 outpatient visits 
or 1 inpatient hospitalization were identiﬁed from a U.S. commercial database 
(January 1, 2004 to March 1, 2008). Patients started on a depot antipsychotic (no 
depot injection in the prior 6 months) were studied in a “mirror image” design to 
assess change in psychiatric hospitalization rates, the mean duration and cost of 
hospitalization between the 6 months prior versus 6 months post medication initiation. 
Cost comparisons were conducted with paired t-test and bootstrapping methods. 
RESULTS: A total of 147 patients with schizophrenia were in the analysis. Compared 
to the six months prior to depot initiation, the rate of psychiatric hospitalization in 
the six months post-initiation declined from 49.7% to 22.5% (p < 0.001); the mean 
hospitalized duration for psychiatric purposes numerically declined from 7.3 to 4.7 
days (p = 0.08). The change in total health care costs declined from $11,111 to $7,884 
and was driven by the reduction in costs for psychiatric hospitalizations from $5,384 
to $2,537 (cost offset of $-2,847). CONCLUSIONS: The initiation of depot antipsy-
chotic therapy appears to be associated with declines in hospitalization rates and 
hospitalization costs. Current ﬁndings suggest that treatment with depot antipsychot-
ics is a cost-effective option for a subgroup of patients with schizophrenia who are at 
high risk of nonadherence with their oral antipsychotic medication regimen.
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OBJECTIVES: Investigate the relationship between persistence with antipsychotic 
drug therapy and treatment costs in patients with schizophrenia. METHODS: A 
retrospective database study was performed using Medi-Cal data from 1994 to 2003. 
Patients with schizophrenia were identiﬁed using ICD-9 codes. A total of 238,754 
episodes of psychotropic drug therapy were used to estimate a series of ordinary least 
squares (OLS) regression models of post-treatment cost as a function of alternative 
deﬁnitions of persistence. All models adjusted for baseline independent variables 
including demographics, drug use history, prior medical care use and co-morbid 
medical conditions. RESULTS: Our primary model compared ‘gold standard’ persis-
tence patients [deﬁned as achieving one year of continuous therapy with no augmenta-
tion or switching] to other classiﬁcations of persistent and non-persistent behavior. 
The least expensive patients were quitters [-$1484] and patients who use their initial 
medication intermittently [-$1791] primarily due to having lower drug costs. Patients 
who were persistent on their initial drug while adding a second drug and patients who 
achieved one year of persistence on their added drug were signiﬁcantly more costly to 
treat than ‘gold standard’ patients [+$1935 and +$3185, respectively] [p < 0.0001 for 
all estimates]. CONCLUSIONS: These results suggest that the intermittent use of 
psychotropic medications may be a cost-effective treatment strategy for some patients. 
However, low cost and intermittent use may also indicate that the patient has with-
drawn from contact with the health care system. Conversely, patients who experience 
costly, sub-optimal outcomes may tend to add or switch drugs while maintaining 
uninterrupted therapy. Clearly, using persistence as a measure of drug performance 
in comparative effectiveness research may be misleading without data on switching 
and severity of illness. As a result, medications used to treat more severe patients may 
appear to be the most expensive medications when compared head-to-head with 
medications used to treat intermittent therapy patients.
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OBJECTIVES: Health plans monitor daily dosing of pharmaceuticals by calculating 
daily average consumption (DACON) and average daily cost ($ADC) on the basis of 
aggregate pharmacy data We examined DACON and $ADC for duloxetine-treated 
patients with 1 or more disorders for which duloxetine has received FDA approval. 
METHODS: This retrospective analysis examined US commercially insured patients 
who received ≥1 prescription of duloxetine during 2008 for 1 or more of the following 
disorders: major depressive disorder (MDD), diabetic peripheral neuropathic pain 
(DPNP), generalized anxiety disorder (GAD), or ﬁbromyalgia (FM). Patients were 
assigned to subgroups by indication based on diagnosis codes recorded during the 12 
months prior to their ﬁrst recorded duloxetine prescription during the study interval. 
DACON was calculated by dividing total pills dispensed by total days of supply. 
$ADCs were calculated using June 2009 new wholesale prices. RESULTS: There were 
47,089 duloxetine-treated patients from 2008 included in the analysis, 28,313 with 
diagnosed MDD, 16,285 with FM, 5,769 with GAD, and 2,575 with DPNP. Overall 
DACON for duloxetine among all patients was 1.34 capsules per day, and $ADC was 
$5.44. For duloxetine-treated patients with MDD only (no GAD, DPNP, or FM), 
DACON and $ADC were 1.42 and $5.62, respectively. For patients with FM only, 
DACON/$ADC were 1.28/$5.10; for GAD only, 1.25/$4.96; and for DPNP only, 
1.25/$4.99. DACON and $ADC were higher among patients with both MDD and 
another indicated disorder: 1.52/$6.06 for MDD and FM; 1.47/$5.85 for MDD and 
GAD, and 1.50/$5.98 for MDD and DPNP. CONCLUSIONS: DACON and $ADC 
for duloxetine were higher for patients with MDD alone than for patients with GAD, 
DPNP, or FM alone. DACON and $ADC were somewhat higher for patients with 
MDD and another indicated disorder than for MDD alone, though there was little 
variation in these measures with respect to which indication MDD was paired.
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OBJECTIVES: Treatment adherence for a sufﬁcient duration is important in the treat-
ment of major depressive disorder (MDD). This study examined the association 
between treatment persistence with duloxetine and health care costs in the year after 
medication initiation. METHODS: In a large U.S. commercial managed-care claims 
database, 4542 patients (18 to 64 years old) with at least 1 claim with a diagnosis of 
MDD (ICD-9-CM: 296.2 and 296.3) were initiated on duloxetine during 2006. 
Patients were included if they had no active prescription of duloxetine during the 6 
months prior to initiation and had continuous enrollment for 12 months prior to and 
post-duloxetine initiation. Treatment persistence was deﬁned as the length of therapy 
without exceeding a 30-day gap. A general linear model regression was performed to 
examine the associations between treatment persistence and health care costs in the 
post 1 year. RESULTS: Overall, average length of duloxetine therapy was 116.0 days 
(SD = 63.5) in the post 6 months; 62.8% of patients stayed on the medication for 
more than 3 months. Signiﬁcant associations between persistence and health care costs 
were observed. With prolonged length of therapy (<31 days, 31–90 days, >90 days), 
average total health care costs were signiﬁcantly reduced ($25,499, $18,438, and 
$17,255, p = .020). Speciﬁcally, medical costs were signiﬁcantly reduced ($21,338, 
$14,123, and $11,496, p = 0.009), while pharmacy costs were increased ($4,161, 
$4,316, and $5,759, p < 0.001). After adjustment for baseline demographics, comor-
bid conditions, and health care costs, results were essentially unchanged. Adjusted 
total health care costs were $20,162, $13,821, and $13,706 for patients who stayed 
on the medication for <31 days, 31–90 days, and >90 days, respectively. CONCLU-
